OOIR: Observatory of International Research

Papers

(The TQCC of Cancer Chemotherapy and Pharmacology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Quantitative proteomics profiling reveals the inhibition of trastuzumab antitumor efficacy by phosphorylated RPS6 in gastric carcinoma	132
Pharmacogenomic associations of cyclophosphamide pharmacokinetic candidate genes with 4hydroxycyclophosphamide formation in children with Cancer	41
Pazopanib and antacids: insights from the WHO pharmacovigilance database	31
Population pharmacokinetics of ruxolitinib in children with hemophagocytic lymphohistiocytosis: focus on the drug–drug interactions	31
A clinical scoring tool validated with machine learning for predicting severe hand–foot syndrome from sorafenib in hepatocellular carcinoma	30
Determination of 5-azacitidine in human plasma by LC–MS/MS: application to pharmacokinetics pilot study in MDS/AML patients	28
A polo-like kinase 1 inhibitor enhances erastin sensitivity in head and neck squamous cell carcinoma cells in vitro	25
Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide	23
Impact of previous corticosteroid exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective observational study	23
Comment on: Dose adjustment strategy for high dose methotrexate-induced toxicities in pediatric acute lymphoblastic leukemia: based on population PK analysis and exposure toxicity relationship	20
Correlation analysis between camrelizumab trough concentration levels and efficacy or safety in East Asian patients with advanced lung cancer	20
Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations	20
Biotransformation and disposition of C14-labeled sonrotoclax ([14C]BGB-11417) in preclinical safety species and characterization of unique contribution from gut microbiome	20
Exposure–response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma	19
Plasma clearance of 5-fluorouracil is more influenced by variations in glomerular filtration rate than by uracil concentration	18
Pharmacokinetics of cisplatin in the systemic versus hyperthermic intrathoracic or intraperitoneal chemotherapy	18
Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review	18
Effects of cyclophosphamide related genetic variants on clinical outcomes of adult hematopoietic cell transplant patients	17
Correction: HER-2 SMASH	17
A case report: capillary leak syndrome in a patient receiving high-dose methotrexate, Tislelizumab and zanubrutinib for CNS lymphoma	16
Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical s	16
A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer	16
Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapy	16
Population pharmacokinetic analysis of bevacizumab in Japanese cancer patients with proteinuria: a prospective cohort study	15
Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study	15

Retraction Note: NO donor inhibits proliferation and induces apoptosis by targeting PI3K/AKT/mTOR and MEK/ERK pathways in hepatocellular carcinoma cells	15
Optimized scaling of translational factors in oncology: from xenografts to RECIST	14
Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report	14
Efficacy and safety exposure–response analyses of entrectinib in patients with advanced or metastatic solid tumors	13
Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors	13
A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma	13
Assessment of cytochrome P450 3A4-mediated drug–drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model	13
Real-world pharmacokinetics of trametinib in pediatric low-grade glioma	12
Nanotechnology and nanobots unleashed: pioneering a new era in gynecological cancer management – a comprehensive review	12
Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach	12
Anti-tumor efficacy of RAF/MEK inhibitor VS6766 in KRAS-mutated colorectal cancer cells	12
An interactive dose optimizer based on population pharmacokinetic study to guide dosing of methotrexate in Chinese patients with osteosarcoma	12
Combination of S-1 and the oral ATR inhibitor ceralasertib is effective against pancreatic cancer cells	11
Emetine, a small molecule natural product, displays potent anti-gastric cancer activity via regulation of multiple signaling pathways	11
Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406)	11
Targeted therapy of angiogenesis using anti-VEGFR2 and anti-NRP-1 nanobodies	11
Alternative routes of drug administration: exposure of imatinib using different formulations	11
Immunoregulatory cyclophilin a improves low-dose chemotherapy with a modulation of the immune tumor microenvironment in experimental models of melanoma B16 and lymphoma EL4 in vivo	11
Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers	11
Platinum-based chemotherapy in metastatic prostate cancer: what possibilities?	11
Fluoropyrimidine-associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>A: impact of haplotype	11
Hsp90 inhibition sensitizes DLBCL cells to cisplatin	11
The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects	11
Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation	10
Successful use of Palbociclib combined with Venetoclax and Azacitidine in an adult with refractory/relapsed therapy-related acute myeloid leukemia	10
Peptides derived from the POU domain of BRN2 show antitumor activity against murine melanoma model cells in vitro and in vivo	10
SOX8 promotes cetuximab resistance via HGF/MET bypass pathway activation in colorectal cancer	10
HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of anti-PD-1/PD-L1 antibody in NSCLC	10
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors	10
Aclarubicin: contemporary insights into its mechanism of action, toxicity, pharmacokinetics, and clinical standing	10
18β-glycyrrhetinic acid suppresses Lewis lung cancer growth through protecting immune cells from ferroptosis	9
Dihydropyrimidine enzyme activity and its effect on chemotherapy toxicity: importance of genetic testing	9
RETRACTED ARTICLE: New recommendations for reversal of high-dose methotrexate cytotoxicity with folinic acid	9
Physiologically based pharmacokinetic modeling of ponatinib to describe drug–drug interactions in patients with cancer	9
Risk factors of proteinuria and potentially protective effect of renin–angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib	9
Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole	9
Pharmacokinetics, mass balance, and metabolism of [14C]FCN-437c, a selective and potent CDK4/6 inhibitor in humans	9
Retraction Note: Induction of apoptosis by [6]-gingerol associated with the modulation of p53 and involvement of mitochondrial signaling pathway in B[a]P-induced mouse skin tumorigenesis	9
Combined treatment of All-trans retinoic acid with Tamoxifen suppresses ovarian cancer	8
Cytidine deaminase enzyme activity is a predictive biomarker in gemcitabine-treated cancer patients	8
Assessing plastic waste associated with LC-MS/MS method validation procedures	8
Avermectin B1 mediates antitumor activity and induces autophagy in osteosarcoma through the AMPK/ULK1 signaling pathway	8
Evaluating the indotecan–neutropenia relationship in patients with solid tumors by population pharmacokinetic modeling and sigmoidal Emax regressions	8
Targeting insulin-like growth factor-1 (IGF-1) by using metformin in non-diabetic metastatic breast cancer female patients: a randomized controlled trial	8
A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors	8
Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial	8
A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors	8
Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs	8
Effects of infliximab, an anti-TNF-α, on cyclophosphamide-induced bone marrow toxicity	8
Assay performance and stability of uracil and dihydrouracil in clinical practice	7

Mass balance, metabolic disposition, and pharmacokinetics of a novel selective inhibitor of PI3Kδ [14C] SHC014748M in healthy Chinese subjects following oral administration	7
Gene polymorphisms of TACR1 serve as the potential pharmacogenetic predictors of response to the neurokinin-1 receptor antagonist-based antiemetic regimens: a candidate-gene association study in breas	7
PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma	7
Pharmacokinetic exposure and treatment outcomes of lenvatinib in patients with renal cell carcinoma and differentiated thyroid carcinoma	7
Somatic nuclear auto-antigenic sperm protein sensitizes human breast cancer cells to 5-Fluorouracil	7
Removal rate of 5-fluorouracil and its metabolites in patients on hemodialysis: a report of two cases of colorectal cancer patients with end-stage renal failure	7
Protective effect of celecoxib against capecitabine induced hand and foot syndrome in patients with colorectal Cancer	7
Repurposed antipsychotic chlorpromazine inhibits colorectal cancer and pulmonary metastasis by inducing G2/M cell cycle arrest, apoptosis, and autophagy	7
PARP1 promotes EGFR-TKI drug-resistance via PI3K/AKT pathway in non-small-cell lung cancer	7
Pazopanib pharmacokinetically guided dose optimization in three cancer patients with gastrointestinal resection	6
Exposure–response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma	6
Prognostic value of RRM1 and its effect on chemoresistance in pancreatic cancer	6
Cabozantinib-induced serum creatine kinase elevation and rhabdomyolysis: a retrospective case series	6
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mu	6
Clinical significance of KL-6 in immune-checkpoint inhibitor treatment for non-small cell lung cancer	6
A novel Ondansetron extended release injectable suspension (OERIS): evaluation of Safety, tolerability and pharmacokinetics in a phase I trial	6
Population pharmacokinetic and exposure-toxicity analyses of nab-paclitaxel after pegylated recombinant human granulocyte colony-stimulating factor administration in patients with metastatic breast ca	6
Effects of splicing-regulatory polymorphisms in ABCC2, ABCG2, and ABCB1 on methotrexate exposure in Chinese children with acute lymphoblastic leukemia	6
Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer	6
Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies	6
A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies	6
Correction to: Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants	6
Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia	6
Veratricplatin inhibits the progression of hypopharyngeal squamous cell carcinoma FaDu cells in vitro and in vivo	6
Adaptive dosing of sunitinib in a metastatic renal cell carcinoma patient: when in silico modeling helps to go quicker to the point	6
Ruthenium–dihydroartemisinin complex: a promising new compound for colon cancer prevention via G1 cell cycle arrest, apoptotic induction, and adaptive immune regulation	6
A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome	6
Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors	6
Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors	6
Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomas	6
Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer	6
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes	6
Pharmacokinetic and bioequivalence study of two capecitabine tablets in Chinese patients with solid tumor cancer	6
Bioequivalence, food effect and comparative pharmacokinetics of SUVN-1105, a novel granule formulation of abiraterone acetate, to Zytiga in healthy male subjects	5
Expression of molecular markers and synergistic anticancer effects of chemotherapy with antimicrobial peptides on glioblastoma cells	5
Differential tumor inhibitory effects induced by HER3 extracellular subdomain-specific mouse monoclonal antibodies	5
Inhibiting TROP2 in advanced non-small-cell lung cancer with sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan: similarities and differences	5
The Gustave Roussy Immune score is a powerful biomarker for predicting therapeutic resistance to chemotherapy in gastric cancer patients	5
Therapeutic drug monitoring of immune checkpoint inhibitors: based on their pharmacokinetic properties and biomarkers	5
Clinical pharmacology and therapeutic applications of talazoparib: a comprehensive review	5
Association between chemotherapy-induced myelosuppression and curative efficacy of 2-cycle chemotherapy in small cell lung cancer	5
Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-	5
Correction to: An IQ consortium analysis of starting dose selection for oncology small molecule first‑in‑patient trials suggests an alternative NOAEL‑based method can be safe while reducing time to th	5
A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer	5
Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma	5
Non-linear IV pharmacokinetics of the ATR inhibitor berzosertib (M6620) in mice	5
Targeting pan-essential pathways in cancer with cytotoxic chemotherapy: challenges and opportunities	5
Prospective validation of an equation based on plasma cystatin C for monitoring the glomerular filtration rate in children treated with cisplatin or ifosfamide for cancer	5
Characterization of exposure–response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study	5
Variations in serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment	5
Distribution of therapeutic monoclonal antibodies into ascites in advanced gastric cancer patients with peritoneal metastasis: case reports and literature review	5
Adjuvant treatment with Capecitabine in patients who received orthotopic liver transplantation with incidental diagnosis of intrahepatic cholangiocarcinoma. Implications on DPYD polymorphisms assessme	5
A case report of typhlitis during novel use of ropidoxuridine–capecitabine–radiotherapy for treatment-naïve rectal cancer	5
Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma	5
Effects of a novel toll-like receptor 4 antagonist IAXO-102 in a murine model of chemotherapy-induced gastrointestinal toxicity	5
Correction to: Phase I study of the anti‑TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors	5
Evaluation of cytogenetic and molecular markers with MTX-mediated toxicity in pediatric acute lymphoblastic leukemia patients	5
SMAGP regulates doxorubicin sensitivity in triple-negative breast cancer cells via modulating mitochondrial respiration	5
Prediction of ROS1 and TRKA/B/C occupancy in plasma and cerebrospinal fluid for entrectinib alone and in DDIs using physiologically based pharmacokinetic (PBPK) modeling approach	5
Idiopathic hyperammonemic encephalopathy secondary to gemcitabine–cisplatin treatment	5
Intestinal toll-like receptor 4 knockout alters the functional capacity of the gut microbiome following irinotecan treatment	5
Continuous 72-h infusion of zosuquidar with chemotherapy in patients with newly diagnosed acute myeloid leukemia stratified for leukemic blast P-glycoprotein phenotype	5
Assessing pharmacokinetics and drug-drug interactions of the combination therapy of myelofibrosis with ruxolitinib and lenalidomide by a new eco-friendly HPLC method for their simultaneous determinati	5
The effects of pazopanib on doxorubicin pharmacokinetics in children and adults with non-rhabdomyosarcoma soft tissue sarcoma: a report from Children’s Oncology Group and NRG Oncology study ARST1321	5